Therapy Name | HM-3 |
Therapy Description |
HM-3 is a synthetic peptide derived from endostatin, which targets integrin alpha v beta 3, possibly resulting in inhibition of angiogenesis and tumor growth (PMID: 27633584). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HM-3 | HM-3 is a synthetic peptide derived from endostatin, which targets integrin alpha v beta 3, possibly resulting in inhibition of angiogenesis and tumor growth (PMID: 27633584). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | Unknown unknown | colon cancer | not applicable | HM-3 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a colon cancer cells treated with HM-3 demonstrated reduced cell migration in culture and inhibition of tumor growth in xenograft models (PMID: 27633584). | 27633584 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|